Show simple item record

dc.contributor.authorGedikli, Mustafa Asım
dc.contributor.authorTüzün, Burak
dc.contributor.authorSayın, Koray
dc.contributor.authorAtaseven, Hilmi
dc.date.accessioned2022-05-17T05:10:30Z
dc.date.available2022-05-17T05:10:30Z
dc.date.issued2021tr
dc.identifier.urihttps://hdl.handle.net/20.500.12418/13143
dc.description.abstractBACKGROUND: It is the SARS-CoV-2 virus, one of the most signifi cant diseases of today’s world. Due to the high transmission of this disease, studies are ongoing to discover an inhibitor drug that can stop this disease. In this study, inhibitory drugs used for many diseases were tried to stop the SARS-CoV-2 virus. AIM: In the calculations made, inhibitor molecules for the SARS-CoV-2 virus were calculated by molecular docking method. RESULTS AND CONCLUSION: Inhibitory activities of SARS-CoV-2 virus against spike glycoprotein (PDB ID: 6M0J, 6LZG), main protease (PDB ID: 5RGG, 6WTT), and RNA dependent RNA polymerase (RdRp) (PDB ID: 6YYT, 7BV2) proteins were compared. Then, docking calculations were supported by calculations by MM-PSBA of the inhibitor with the highest activity. Afterwards, it was compared with FDA approved drugs for the SARS-CoV-2 virus. It was found that the Carvedilol molecule was the best against RNA dependent RNA polymerase (RdRp) protein of SARS-CoV-2 (Tab. 4, Fig. 9, Ref. 42).tr
dc.language.isoengtr
dc.rightsinfo:eu-repo/semantics/restrictedAccesstr
dc.titleDetermination of inhibitor activity of drugs against the COVID-19tr
dc.typearticletr
dc.contributor.departmentFen Fakültesitr
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıtr


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record